Toruner, Gokce A <br/><br/>
Low ALK FISH positive metastatic non-small cell lung cancer (NSCLC) patients have shorter progression-free survival after treatment with ALK inhibitors.  [electronic resource] 

 -  Cancer genetics  02 2020 
 - 57-60 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article 
<br/><br/><label>ISSN: </label>2210-7762 
<br/><br/><label>Standard No.: </label>10.1016/j.cancergen.2019.12.003  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Anaplastic Lymphoma Kinase--analysis<br/>Carbazoles--pharmacology<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>Clinical Decision-Making--methods<br/>Crizotinib--pharmacology<br/>False Positive Reactions<br/>Female<br/>Follow-Up Studies<br/>Gene Rearrangement<br/>Humans<br/>In Situ Hybridization, Fluorescence--statistics & numerical data<br/>Lung Neoplasms--drug therapy<br/>Male<br/>Middle Aged<br/>Piperidines--pharmacology<br/>Progression-Free Survival<br/>Proportional Hazards Models<br/>Protein Kinase Inhibitors--pharmacology<br/>Retrospective Studies